Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus is a metabolic disease of carbohydrate metabolism. However, it should also be considered a vascular disease because diabetic patients have a strong predilection for atherosclerosis. With the increasing prevalence and earlier age at onset of diabetes, the projected effect of diabetes on cardiovascular health and resource utilization is sobering. The mechanisms of the high rate of atherosclerosis are multifactorial and give clinicians and researchers insights into potential preventive therapies. Effective pharmacologic and lifestyle interventions are available for primary and secondary prevention of cardiovascular complications. However, data show that these interventions continue to be underutilized. Treatment of patients with type 2 diabetes and coronary artery disease is similar to that of patients with coronary artery disease alone. However, patients with diabetes benefit more from treatments that reduce coronary artery disease risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“The Steno-2 trial showed that a multifactorial intervention (Table 4) on modifiable risk factors in diabetic patients with microalbuminuria (urinary albumin level, 30 to 250 mg/dL) decreased cardiovascular and microvascular events by more than 50% compared with conventional treatment (45).”
BackgroundStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 1×
“The Multiple Risk Factor Intervention Trial showed that the number of deaths from coronary artery disease doubled in diabetic persons with 1 additional risk factor and more than tripled with 3 additional risk factors (44).”
BackgroundRubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“In the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial, treatment with gemfibrozil reduced the risk for myocardial infarction by 24% in diabetic patients but showed no benefit in terms of mortality rate (60).”
BackgroundGerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440 · cited 1×
“It may also be a surrogate marker for cardiovascular disease and early cardiovascular mortality (54) and a predictor of long-term outcome after percutaneous coronary intervention.”
Background
Cited by
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes
Wexler, D. J., Grant, R. W., Meigs, J. B., Nathan, D. M., & Cagliero, E. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.514 · Cited by 339
Kostis, J. B., Wilson, A. C., Freudenberger, R. S., Cosgrove, N. M., Pressel, S. L., & Davis, B. R. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.059 · Cited by 325
MicroRNA in ischemic stroke etiology and pathology
Rink, C., & Khanna, S. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2010 · Cited by 255
Okon, E. B., Chung, A. W. Y., Zhang, H., Laher, I., & van Breemen, C. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y07-026 · Cited by 50
Metadata
- Authors
- Hurst, R. T., & Lee, R. W.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2003-11-18
- Volume
- 139
- Issue
- 10
- Pages
- 824-834
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2038051506
- Cited by
- 139
- References
- 23
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management. https://app.cochat.ai/papers/10.7326/0003-4819-139-10-200311180-00010
- The paper
- Hurst, R. T., & Lee, R. W. (2003). Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-139-10-200311180-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.